frontiers | Frontiers in Cell and Developmental Biology

TYPE Correction
PUBLISHED 09 September 2022
DOI 10.3389/fcell.2022.1002132

OPEN ACCESS

EDITED AND REVIEWED BY
Claudia Fiorillo,
University of Florence, Italy

*CORRESPONDENCE
Zhiwei Jie,
jiezhiwei@zju.edu.cn

†These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology

RECEIVED 25 July 2022
ACCEPTED 18 August 2022
PUBLISHED 09 September 2022

CITATION
Jiang C, Ma Q, Wang S, Shen Y, Qin A, Fan S and Jie Z (2022), Corrigendum: Oxymatrine attenuates osteoclastogenesis via modulation of ROS-mediated SREBP2 signaling and counteracts ovariectomy-induced osteoporosis.
Front. Cell Dev. Biol. 10:1002132.
doi: 10.3389/fcell.2022.1002132

Corrigendum: Oxymatrine attenuates osteoclastogenesis via modulation of ROS-mediated SREBP2 signaling and counteracts ovariectomy-induced osteoporosis

Chao Jiang[1,2†], Qingliang Ma[1,2†], Shiyu Wang[1,2], Yang Shen[1,2], An Qin[3], Shunwu Fan[1,2] and Zhiwei Jie[1,2*]

[1]Department of Orthopaedics, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, [2]Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Hangzhou, China, [3]Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

KEYWORDS

oxymatrine, osteoclast, ROS, SREBP2, osteoporosis

A Corrigendum on
Oxymatrine attenuates osteoclastogenesis via modulation of ROS-mediated SREBP2 signaling and counteracts ovariectomy-induced osteoporosis

by Jiang C, Ma Q, Wang S, Shen Y, Qin A, Fan S and Jie Z (2021). Front. Cell Dev. Biol. 9:684007. doi: 10.3389/fcell.2021.684007

In the original article, there were mistakes in Figures 1, 3 as published. The scale bars of TRAP staining images in Figures 1D, 3J were incorrect. Furthermore, we applied a mismatched picture for Figure 1F. The corrected Figures 1, 3 appear below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 1
OMT inhibits RANKL-induced osteoclast formation and activity *in vitro*. **(A)** The chemical structure and formula of OMT. **(B,C)** Cell viability of OMT-treated BMMs at 48 and 96 h **(D)** BMMs were stimulated by 30 ng/mL M-CSF and 50 ng/mL RANKL, and treated with indicated concentrations of OMT for 5 days. Representative images of TRAP staining and F-actin staining were shown. Scale bar = 200 μm. **(E)** Quantification of TRAP-positive multinuclear cells and F-actin ring formation rate. **(F)** BMMs were stimulated with 30 ng/mL M-CSF and 50 ng/mL RANKL for 7 days, and treated with 200 μM OMT for the indicated days. TRAP staining and F-actin ring staining were performed. Scale bar = 200 μm. **(G)** Quantification of TRAP-positive multinuclear cells and F-actin ring formation rate. **(H)** Representative images of bone resorption pits. Scale bar = 500 μm. **(I)** Quantification of resorption pit area in each group. Data were presented as means ± SD of 5 independent experiments. *$p < 0.05$, ***$p < 0.001$.



FIGURE 3
OMT attenuates SREBP2 activity and downstream NFATc1 expression during osteoclastogenesis. **(A)** BMMs were stimulated with RANKL, with or without 200 μM OMT for 0, 1, 3, 5 days, the expression of NFATc1, CTSK and TRAP was tested by western blots. **(B–D)** Quantification of the ratios of band intensity of NFATc1, TRAP, and CTSK relative to β-actin (n = 3 per group). **(E)** BMMs were treated with RANKL and 200 μM OMT as indicated, western blot was used to detect the level of pre-SREBP2 and active-SREBP2. **(F)** Quantification of active-SREBP2/pre-SREBP2 ratio (n = 3 per group). **(G)** RAW264.7 cells were treated with RANKL and OMT as indicated, immunofluorescence assay was performed to detect SREBP2 translocation. Scale bar = 100 μm. **(H)** BMMs were transfected with Flag-SREBP2 plasmid or empty vector, then treated with RANKL and OMT as indicated, the expression of NFATc1 was examined. **(I)** Quantification of NFATc1/β-actin ratio (n = 3 per group). **(J)** BMMs were transfected with Flag-SREBP2 plasmid or empty vector, then treated with RANKL and OMT as indicated. Representative images of TRAP staining were shown. Scale bar = 200 μm. **(K)** Quantification of TRAP-positive multinuclear cells per well (n = 5 per group). **(L)** ChIP assay was performed on BMMs, treated with RANKL and OMT as indicated. Data were presented as means ± SD. $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

Publisher's note